What
other approvals are needed?
- Recombinant DNA and Gene Transfer Approval
- FDA Drug or Device Studies Approval
- Stem Cell Study Approval
The NIH
Guidelines for Recombinant DNA and Gene Transfer state
that no research participant will be enrolled in gene transfer
studies (Phase I, II, or III) until the Recombinant DNA
Advisory Committee (RAC ) review has been completed, Institutional
Review Board (IRB) and Institutional Biosafety Committee (IBC) approvals
have been obtained, and an Investigational New Drug request
has been authorized. NIH Guidelines apply to investigators
conducting gene transfer research that are supported by
NIH or performed at an Institution that receives NIH support
for any type of recombinant DNA research.
FDA approvals
are required for studies that use:
- An unapproved or unlicensed drug or device.
- An FDA licensed drug or device used in a manner for
which it has not been licensed (“off label use”).
- A drug or device formulated or developed by an organization
that does not hold an FDA license for its manufacture.
- An unapproved or unlicensed gene delivery vector containing
a gene or DNA product.
You may need to obtain an IND or IDE approval
for your study drug or device. A physician who both initiates
and conducts an investigation in which an investigational
drug is administered or dispensed may submit an Investigator
IND. For more information, see the FDA website on the Investigational
New Drug Application Process.
If your study proposal involves an investigational
device, you may find more information at FDA
Device Advice.
Studies that involve stem cells or human
fetal tissue must comply with established federal policies. Stem
Cell Information is available from NIH and includes
federal policy, guidelines and FAQ's. Human
Embryo Research, Cloning and Transplantation describes
the policy for NIH funding in this area. |
